Table S1.

Sensitivity analyses of subgroup based on the number of patients with exacerbations and adverse effects

	Number of patients with exacerbations			Adverse effects
	Studies (n)	OR (95% CI)	P-value	Studies (n)	OR (95% CI)	P-value
Azithromycin	4	0.37 (0.21–0.67)	0.001	4	1.38 (0.69–2.78)	0.36
Erythromycin	3	0.22 (0.09–0.53)	0.0008	3	1.23 (0.57–2.65)	0.6
Clarithromycin	1	3.27 (0.59–18.21)	0.18	1	3.27 (0.59–18.21)	0.18
Roxithromycin	0	NA	NA	1	3.21 (1.56–6.60)	0.002
Three-month treatment	4	0.60 (0.26–1.42)	0.25	5	2.06 (1.27–3.35)	0.004
Six-month treatment	2	0.17 (0.04–0.75)	0.02	2	2.01 (0.51–7.86)	0.32
Twelve-month treatment	3	0.20 (0.08–0.47)	0.0002	3	2.16 (1.03–4.53)	0.04

Abbreviation: NA, data not available.